BridgeBio Oncology Therapeutics Inc. – Material Contracts Watch

from 10-Q 6 pages Consulting Agreement

from 10-Q 6 pages May 11, 2026 Idan Elmelech Re: Employment Agreement and Executive Severance Plan Participation Agreement Dear Idan

from 10-Q 7 pages May 11, 2026 Dr. Pedro Beltran Re: Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement Dear Pedro

from 10-Q 4 pages Amendment No. 9 to Transition Services Agreement 1

from 10-Q 3 pages Amendment No. 8 to Transition Services Agreement 1. 2

from 10-Q 45 pages Leidos Biomedical Cooperative Research and Development Agreement

from 10-Q 48 pages Stevenson-Wydler (15 Usc 3710a) Cooperative Research and Development Agreement Between Lawrence Livermore National Security, LLC and Theras, Inc. for Discovery of Novel Ras Inhibitors Llnl Case No. Tc02290.0 Lawrence Livermore National Laboratory Lawrence Livermore National Security, LLC, Livermore, Ca 94551 Innovation and Partnerships Office May 8, 2018

from 10-K 3 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to Patent License Agreement – Exclusive License Number 0486 (“Amendment No. 1”) Effective Date: December 18, 2025

from 10-K 3 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to Patent License Agreement – Exclusive License Number 0421

from 10-K 3 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment No. 1 to Patent License Agreement – Exclusive License Number 0401

from 10-K 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment One to Limited Exclusive Patent License Agreement for Kras G12c Inhibitors Between Lawrence Livermore National Security, LLC and Theras, Inc. Llnl Case No. Tl02796 Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779, Livermore, Ca 94551 November 18, 2025

from 10-K 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment One to Limited Exclusive Patent License Agreement for Pi3ka Breakers Between Lawrence Livermore National Security, LLC and Theras, Inc. Llnl Case No. Tl02797 Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779, Livermore, Ca 94551 November 18, 2025

from 10-K 3 pages BridgeBio Oncology Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy

from 10-K 4 pages Amendment No. 7 to Transition Services Agreement 1

from 10-K 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Amendment One to Limited Exclusive Patent License Agreement for Pan-Kras Inhibitors Between Lawrence Livermore National Security, LLC and Theras, Inc. Llnl Case No. P2025-0121 Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779, Livermore, Ca 94551 November 18, 2025 Amendment One November 18, 2025 to License Agreement - Llnl Case Number P2025-0121 for Pan-Kras Inhibitors Between Lawrence Livermore National Security, LLC and Theras, Inc. Effective December 20, 2024

from 10-Q 4 pages Amendment No. 6 to Transition Services Agreement

from 10-Q 5 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because the Registrant Has Determined That It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. August 11, 2025 BridgeBio Pharma LLC BridgeBio Services, Inc. 3160 Porter Drive, Suite 250 Palo Alto, Ca 94304 Re: Amendment and Supplement to Transition Services Agreement Ladies and Gentlemen

from 10-Q 4 pages Amendment No. 4 to Transition Services Agreement

from 10-Q 4 pages Amendment No. 3 to Transition Services Agreement

from 10-Q 5 pages Amendment No. 2 to Transition Services Agreement